1 / 14

Aarkstore - Plantacor, Inc. - Product Pipeline Review - 2014

"Plantacor, Inc. - Product Pipeline Review - 2014" report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications.

addyparker2350
Download Presentation

Aarkstore - Plantacor, Inc. - Product Pipeline Review - 2014

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Category : Pharmaceuticals & Healthcare Plantacor, Inc. - Product Pipeline Review - 2014 Browse Complete Report - http://www.aarkstore.com/pharmaceuticals-healthcare/63688/plantacor-inc-product-pipeline-review

  2. Regado Biosciences, Inc. - Product Pipeline Review - 2014

  3. Summary Global Markets Direct’s, ‘Plantacor, Inc. - Product Pipeline Review - 2014’, provides an overview of the Plantacor, Inc.’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Plantacor, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. "Plantacor, Inc. - Product Pipeline Review - 2014" report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

  4. Summary Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

  5. Scope - The report provides brief overview of Plantacor, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Plantacor, Inc.’s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement  - Latest news and deals relating to the Plantacor, Inc.’s pipeline products

  6. Reasons to buy - Evaluate Plantacor, Inc.’s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Plantacor, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Plantacor, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Plantacor, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Plantacor, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  7. Table of Content List of Tables 3List of Figures 3Plantacor, Inc. Snapshot 4Plantacor, Inc. Overview 4Key Information 4Key Facts 4Plantacor, Inc. - Research and Development Overview 5Key Therapeutic Areas 5Plantacor, Inc. - Pipeline Review 7Pipeline Products by Stage of Development 7Pipeline Products - Monotherapy 8Plantacor, Inc. - Pipeline Products Glance 9Plantacor, Inc. - Early Stage Pipeline Products 9

  8. Table of Content Preclinical Products/Combination Treatment Modalities 9Discovery Products/Combination Treatment Modalities 10Plantacor, Inc. - Drug Profiles 11C-Substituted Diindolylmethane Derivatives 11Product Description 11Mechanism of Action 11R&D Progress 11CDIM-9 12Product Description 12Mechanism of Action 12R&D Progress 12CDIM-1 13Product Description 13Mechanism of Action 13

  9. List Of Tables Plantacor, Inc., Key Information 4Plantacor, Inc., Key Facts 4Plantacor, Inc. - Pipeline by Indication, 2014 6Plantacor, Inc. - Pipeline by Stage of Development, 2014 7Plantacor, Inc. - Monotherapy Products in Pipeline, 2014 8Plantacor, Inc. - Preclinical, 2014 9Plantacor, Inc. - Discovery, 2014 10Plantacor, Inc. - Pipeline by Target, 2014 16Plantacor, Inc. - Pipeline by Molecule Type, 2014 17Plantacor, Inc. - Pipeline Products by Mechanism of Action, 2014 18

  10. List of Figures Plantacor, Inc. - Pipeline by Top 10 Indication, 2014 6Plantacor, Inc. - Pipeline by Stage of Development, 2014 7Plantacor, Inc. - Monotherapy Products in Pipeline, 2014 8Plantacor, Inc. - Pipeline by Top 10 Target, 2014 16Plantacor, Inc. - Pipeline by Top 10 Molecule Type, 2014 17Plantacor, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 18

  11. Related Reports • Global Neurosurgery Market 2015-2019 • Active Pharmaceutical Ingredients (API) Market in India 2015-2019 • BrainStorm Cell Therapeutics Inc. (BCLI) - Financial and Strategic SWOT Analysis Review • Ampio Pharmaceuticals, Inc. (AMPE) - Financial and Strategic SWOT Analysis Review • MiMedx Group, Inc (MDXG) - Financial and Strategic SWOT Analysis Review

  12. Related Reports • Threshold Pharmaceuticals, Inc. (THLD) - Financial and Strategic SWOT Analysis Review • MEI Pharma, Inc. (MEIP) - Financial and Strategic SWOT Analysis Review • Titan Pharmaceuticals, Inc. (TTNP) - Financial and Strategic SWOT Analysis Review • RedHill Biopharma Ltd. (RDHL) - Financial and Strategic SWOT Analysis Review • Pharmaceuticals & Healthcare Market Research Reports

  13. Plantacor, Inc. - Product Pipeline Review - 2014Published: Oct 2014 | 21 Pages "Plantacor, Inc. - Product Pipeline Review - 2014" report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Price

  14. Contact Us Office Office No. - 809, 8th Floor,B-Wing, Mahaavir Icon, Plot No.- 89 & 90, Sector-15,CBD-Belapur, Navi Mumbai – 400614, Maharashtra, India. Telefax No: +91 22 4127 6660 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 You Can Visit http://www.aarkstore.com OR Mail us at contact@aarkstore.com Blog : http://www.aarkstore.com/blog/ Conference : http://conference.aarkstore.com/ News : http://www.aarkstore.com/news

More Related